Vaccine efficacy 30% for BNT162b2(Pfizer) and 11 percent for mRNA-1273 (Moderna) against any SARS-CoV-2 infection.
Allergy history may up risk for reactions to mRNA COVID-19 vaccine
Nov 04, 2021
The risk for allergic reactions within three days of vaccination is higher for those with history of high-risk allergy, but most completed the two-dose regimen. The mRNA vaccines approved for use against...
SARS-CoV-2 vaccines effectively prevent infection in VA population
Jul 20, 2021
Vaccine effectiveness was 96.2% for Pfizer-BioNTech BNT162b2 and 98.2% for Moderna mRNA-1273.
Veterans report low rates of adverse events with mRNA vaccines
Jun 16, 2022
Rates were slightly higher at 42 days for those receiving the Pfizer versus Moderna vaccine.
Cardiac complications up after SARS-CoV-2 infection versus vaccines
Apr 06, 2022
“[T]he risks for these complications were higher after infection than after vaccination among males and females in all age groups,” the authors write.
U.S. Surgeon General issues call to counter ‘urgent threat’ of vaccine misinformation
Jul 16, 2021
U.S. Surgeon General Vivek Murthy, M.D., on Thursday called on tech companies, healthcare workers, journalists and ordinary Americans to do more to fight vaccine misinformation.
mRNA COVID-19 vaccine less protective in elderly with comorbidity
Dec 23, 2021
At ≥7 days after the second dose, the effectiveness of mRNA COVID-19 vaccine was 69% against infection and 86% against related death.
COVID-19 boosters could be in the arms of healthcare workers and seniors by early fall
By
Diane Eastabrook
Aug 17, 2021
Healthcare workers and older Americans would be among the first to receive COVID-19 boosters as early as fall, according to National Institutes of Health (NIH) Director Francis Collins, M.D.
Disparities in COVID-19 vaccination identified among healthcare employees
Jun 16, 2021
Vaccination was least likely among clinical nurses, support staff and workers at skilled nursing and rehabilitation facilities.
For dialysis recipients, antibody response lowest with Ad26.COV2.S
Oct 27, 2021
Ad26.COV2.S is the Johnson & Johnson vaccine against COVID-19. Patients receiving the attenuated adenovirus vaccine are more likely to have no seroconversion and no detectable or diminished IgG response.